PPCB - Propanc Biopharma Inc. Debt to Book Capitalization Ratio

Propanc Biopharma Inc (PPCB) develops innovative pro-enzyme agents against solid tumors by targeting cancer stem cells. This total debt-to-equity chart visualizes financial stability, where the value 0.05 represents the current metric. Growth is constrained by stringent FDA regulations and patent costs, while the lack of commercial scale in early stages leads to an increase in unit research costs.

This indicator determines the financial stability of the business through the ratio of borrowed funds to equity. By analyzing the financing structure—debt to book capitalization—the investor assesses the company's degree of dependence on external creditors. The metric is calculated by dividing total liabilities by the value of net assets. A decrease in this ratio minimizes bankruptcy risks but may limit growth rates. For Propanc Biopharma Inc (PPCB), such indicators are critical when financing the development of anti-cancer enzymes in Australia.